BI-4732

Overview

BI-4732 is an orally active, reversible, ATP-competitive EGFR inhibitor with blood-brain barrier penetration. BI-4732 inhibits the kinase activity of EGFR L858R, T790M and C797S with IC 50 values of 1 nM while sparing EGFR wild-type. BI-4732 inhibits EGFR and reduces the phosphorylation of AKT , ERK , and S6K . BI-4732 demonstrates excellent intracranial anti-tumor efficacy in YU-1097 xenograft model harboring EGFR _E19del/T790M/C797S. BI-4732 can be used for the study of non-small cell lung cancer (NSCLC).

Application

Products | Products > Signaling Pathways > JAK/STAT Signaling | Products > Signaling Pathways > Protein Tyrosine Kinase/RTK | Products > Signaling Pathways > PI3K/Akt/mTOR | Products > Signaling Pathways > MAPK/ERK Pathway | Products > Signaling Pathways > Stem Cell/Wnt | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Research Areas > Cancer > Cancer Stem Cells | Products > Research Areas > Cancer > Cancer Metabolism and Metastasis | Products > Signaling Pathways > Ribosomal S6 Kinase (RSK) | Products > Signaling Pathways > EGFR | Products > Signaling Pathways > Akt | Products > Signaling Pathways > ERK

Product Information

• Catalog No.: HY-161275
• CAS No.: 2769715-68-4
• Molecular Formula: C32H36N10O2
• Molecular Weight: 592.69
• Purity: 99.30%
• Storage: 4°C, protect from light * In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
• Availability: In-stock

Source

Original product source